

May 11, 2021

COM-2021-027

Dear provider of healthcare-related services,

On May 10, 2021 the Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age. Originally, the EUA permitted the use in individuals 16 years of age and older.

For additional information, you can refer to:

1. The "[Fact Sheet for Healthcare Providers Administering Vaccine](#)", which has been updated by the FDA to reflect the use of the vaccine in the adolescent population, including the benefits and risks of the Pfizer-BioNTech COVID-19 Vaccine.
2. The [FDA's COVID-19 Vaccines portal](#).
3. The CDC's website.

The situation with the COVID-19 pandemic is dynamic and continuously changing. We strongly encourage the frequent revision of updated information provided by the FDA and the CDC to assure that your practices are consistent with the most actualized information.

PharmPix is committed to our members' health and wellness. It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252, extension 137. Also, you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

Regards,

Clinical Department

References:

1. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. (2021). Retrieved May 2021, from <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use>

